Literature DB >> 1602320

Toxic reaction following the combined administration of fluoxetine and phenytoin: two case reports.

P Jalil.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1602320      PMCID： PMC489092          DOI： 10.1136/jnnp.55.5.412-a

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  4 in total

1.  Inhibition of drug metabolism by fluoxetine.

Authors:  R W Fuller; R C Rathbun; C J Parli
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1976-02

2.  Toxic reaction following the combined administration of fluoxetine and L-tryptophan: five case reports.

Authors:  W Steiner; R Fontaine
Journal:  Biol Psychiatry       Date:  1986-09       Impact factor: 13.382

3.  Fluoxetine: clinical pharmacology and physiologic disposition.

Authors:  L Lemberger; R F Bergstrom; R L Wolen; N A Farid; G G Enas; G R Aronoff
Journal:  J Clin Psychiatry       Date:  1985-03       Impact factor: 4.384

4.  The pharmacologic profile of fluoxetine.

Authors:  P Stark; R W Fuller; D T Wong
Journal:  J Clin Psychiatry       Date:  1985-03       Impact factor: 4.384
  4 in total
  7 in total

Review 1.  Review: Pharmacogenetic aspects of the effect of cytochrome P450 polymorphisms on serotonergic drug metabolism, response, interactions, and adverse effects.

Authors:  J L Pilgrim; D Gerostamoulos; Olaf H Drummer
Journal:  Forensic Sci Med Pathol       Date:  2010-11-04       Impact factor: 2.007

Review 2.  Effects of psychotropic drugs on seizure threshold.

Authors:  Francesco Pisani; Giancarla Oteri; Cinzia Costa; Giorgio Di Raimondo; Raoul Di Perri
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 3.  Clinically significant drug interactions with antidepressants in the elderly.

Authors:  Edoardo Spina; Maria Gabriella Scordo
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 4.  Drug interactions of clinical significance with selective serotonin reuptake inhibitors.

Authors:  P B Mitchell
Journal:  Drug Saf       Date:  1997-12       Impact factor: 5.606

5.  Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions.

Authors:  Adrián LLerena; Pedro Dorado; Roland Berecz; Antonio P González; Eva M Peñas-LLedó
Journal:  Eur J Clin Pharmacol       Date:  2004-01-16       Impact factor: 2.953

Review 6.  Epilepsy, cognition, and neuropsychiatry (Epilepsy, Brain, and Mind, part 2).

Authors:  Amos D Korczyn; Steven C Schachter; Martin J Brodie; Sarang S Dalal; Jerome Engel; Alla Guekht; Hrvoje Hecimovic; Karim Jerbi; Andres M Kanner; Cecilie Johannessen Landmark; Pavel Mares; Petr Marusic; Stefano Meletti; Marco Mula; Philip N Patsalos; Markus Reuber; Philippe Ryvlin; Klára Štillová; Roberto Tuchman; Ivan Rektor
Journal:  Epilepsy Behav       Date:  2013-06-10       Impact factor: 2.937

7.  Mood Disorders in Neurologic Illness.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-03       Impact factor: 3.972
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.